Regulus Therapeutics (RGLS) Expected to Announce Earnings on Thursday

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) is expected to announce its Q4 2024 earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). On average, analysts expect Regulus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Regulus Therapeutics Trading Down 6.8 %

NASDAQ RGLS traded down $0.10 during trading on Thursday, reaching $1.38. The company's stock had a trading volume of 193,056 shares, compared to its average volume of 536,987. The firm has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.47. The firm has a market capitalization of $90.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.41. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.00.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $10.80.

Remove Ads

Insider Activity at Regulus Therapeutics

In related news, CEO Joseph P. Hagan bought 50,000 shares of the company's stock in a transaction on Thursday, January 30th. The shares were purchased at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the purchase, the chief executive officer now directly owns 260,808 shares in the company, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Christopher Ray Aker sold 38,547 shares of the business's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now owns 54,634 shares in the company, valued at $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 223,998 shares of company stock valued at $282,237 over the last 90 days. Insiders own 4.35% of the company's stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.